NGS Analysis for Molecular Diagnosis of Retinitis Pigmentosa (RP): Detection of a Novel Variant in PRPH2 Gene by C. Strafella et al.
genes
G C A T
T A C G
G C A T
Article
NGS Analysis for Molecular Diagnosis of Retinitis
Pigmentosa (RP): Detection of a Novel Variant in
PRPH2 Gene
Claudia Strafella 1,2 , Valerio Caputo 2, Giulia Pagliaroli 1, Nicola Iozzo 3, Giulia Campoli 1,
Stefania Carboni 1, Cristina Peconi 1, Rosaria Maria Galota 1, Stefania Zampatti 1,
Giulietta Minozzi 4 , Giuseppe Novelli 2,5, Emiliano Giardina 1,2,*,† and Ra↵aella Cascella 2,6,†
1 Molecular Genetics Laboratory UILDM, Santa Lucia Foundation, 00179 Rome, Italy;
claudia.strafella@gmail.com (C.S.); giuliapagliaroli90@gmail.com (G.P.);
GIULIACAMPOLI90@gmail.com (G.C.); stefaniacarboni58@gmail.com (S.C.);
cristina.peconi@uildmlazio.org (C.P.); rm.galota@gmail.com (R.M.G.); stefania.zampatti@gmail.com (S.Z.)
2 Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy;
v.caputo91@gmail.com (V.C.); novelli@med.uniroma2.it (G.N.); ra↵aella.cascella@gmail.com (R.C.)
3 Organi di Senso Department, University “la Sapienza”, 00161 Rome, Italy; nicola.iozzo@live.it
4 Department of Veterinary Medicine, University of Milan, 20122 Milan, Italy; giulietta.minozzi@unimi.it
5 Neuromed IRCSS, 86077 Pozzilli, Italy
6 Department of Biomedical Sciences, Catholic University Our Lady of Good Counsel, 1000 Tirana, Albania
* Correspondence: emiliano.giardina@uniroma2.it
† These authors equally contributed to the work.
Received: 18 September 2019; Accepted: 11 October 2019; Published: 12 October 2019
!"#!$%&'(!
!"#$%&'
Abstract: This work describes the application of NGS for molecular diagnosis of RP in a family with a
history of severe hypovision. In particular, the proband received a clinical diagnosis of RP on the basis
of medical, instrumental examinations and his family history. The proband was subjected to NGS,
utilizing a customized panel including 24 genes associated with RP and other retinal dystrophies.
The NGS analysis revealed a novel missense variant (c.668T > A, I223N) in PRPH2 gene, which was
investigated by segregation and bioinformatic analysis. The variant is located in the D2 loop domain
of PRPH2, which is critical for protein activity. Bioinformatic analysis described the c.668T > A as a
likely pathogenic variant. Moreover, a 3D model prediction was performed to better characterize
the impact of the variant on the protein, reporting a disruption of the ↵-helical structures. As a
result, the variant protein showed a substantially di↵erent conformation with respect to the wild-type
PRPH2. The identified variant may therefore a↵ect the oligomerization ability of the D2 loop and,
ultimately, hamper PRPH2 proper functioning and localization. In conclusion, PRPH2_c.668T > A
provided a molecular explanation of RP symptomatology, highlighting the clinical utility of NGS
panels to facilitate genotype–phenotype correlations.
Keywords: Retinitis Pigmentosa; NGS panel; PRPH2; D2 loop domain; genotype-phenotype
correlation
1. Introduction
Retinitis Pigmentosa (RP, OMIM #268000) includes a group of inherited dystrophies involving the
posterior segment of the eye [1]. RP is the most common retinal dystrophy a↵ecting approximately
1:4000 subjects, although prevalence rate depends on geographical localization [2]. RP is one of the
leading causes of hypovision and results from degeneration of the retina. Typically, the damage starts
in the midperipheral part and progressively extends towards the central portion of retina (macula and
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fovea). In fact, the damage is caused by an initial loss of rod photoreceptors, followed by the death of
cone photoreceptors [3] in the later stages of disease. Phenotypic manifestations of RP include night
blindness, impairment of peripheral vision (dysfunction of rod photoreceptors), development of tunnel
vision, progressive decrease of the central visual field (cone dysfunction), and dyschromatopsia [2].
From a clinical point of view, the most significant hallmarks of disease are ocular fundus showing
dark pigmentary clumps, light-colored retinal vessels, cystoid macular edema, and waxy optic disc
pallor [4]. RP can be distinguished in two clinical forms: non-syndromic RP and syndromic RP, which
is usually related to other extra-ocular, systemic symptoms. Both types of disorder can be caused
by rare mutations in several genes which are inherited according to Mendelian patterns (autosomal
dominant, autosomal recessive, X-linked, mitochondrial). To date, more than 80 disease-causing genes
have been implicated in RP, which are mostly involved in the alteration of the structure and function
of photoreceptors and retinal pigment epithelium. However, incomplete penetrance and variable
expressivity generate phenotype and genetic heterogeneity among RP patients [2,5,6]. Generally, RP is
diagnosed by clinical (evaluation of visual acuity) and instrumental (electroretinography, visual field
testing, optical coherence tomography) analysis. The presence of so many causative genes complicates
the selection of reliable and diagnostic genetic assays, although the introduction of Next Generation
Sequencing (NGS) represented a critical point for the improvement of RP molecular diagnosis [7].
In particular, NGS gene panels proved to be highly useful to analyze a set of genes associated with a
specific disease or a group of related disorders, which are characterized by genetic and phenotypic
heterogeneity [8,9]. This is the case of RP, for which the availability of dedicated NGS panels represents
one of the best systems to facilitate di↵erential diagnosis, identify new causative mutations and
clarify genotype–phenotype correlations. In this report, we describe the application of NGS panel for
molecular diagnosis of RP in a family with a clinical history of severe hypovision.
2. Materials and Methods
2.1. Clinical Details
The proband was a↵ected by a severe hypovision which occurred in adulthood. The clinical
assessment was performed at the Sense Organs Department of “Sapienza” University of Rome and
included the visual field testing, ocular fundus inspection, Electroretinography (ERG) test, and Optical
Coherence Tomography (OCT). At the visual acuity testing, the patient resulted in being completely
blind in both eyes. Moreover, the examination of ocular fundus showed the presence of waxy
pallor optic disc, attenuated retinal vessels, bone spicule pigment deposits, macular atrophy in the
mid-periphery, and posterior pole of eyes. The ERG signal was completely undetectable, and the
OCT presented a deeper hyperreflectivity due to the atrophy of neuroepithelium. The patient was
therefore diagnosed with non-syndromic RP and was referred to genetic counselling for the molecular
confirmation of the clinical diagnosis. During the genetic counseling, the patient revealed that both
the deceased father and the paternal grand-mother were blind in both eyes. However, only the father
received a clinical diagnosis of RP. Moreover, the proband also had three siblings. One of them was
also diagnosed with adult-onset RP whereas the other two were referred to be completely healthy,
without any suggestive clinical sign of disease. According to the pedigree (Figure 1) and the family
history, an autosomal dominant form of RP (adRP) was hypothesized.
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Figure 1. Pedigree tree illustrating the possible autosomal-dominant transmission of disease within 
the family of the proband. The red arrow indicates the proband. 
To confirm this hypothesis, the proband and the siblings were subjected to genetic testing to find 
a molecular basis of their phenotypes. The genetic study was performed according to the Declaration 
of Helsinki, and all the participants provided signed informed consent. The study was approved by 
the Ethics Committee of Santa Lucia Foundation (CE/PROG.650 approved on 01/03/2018).  
2.2. Laboratory Investigations 
Genomic DNA was extracted from 400 µL of peripheral blood using MagPurix Blood DNA 
Extraction Kit and MagPurix Automatic Extraction System (Resnova) according to the 
manufacturer’s instructions. The concentration and quality of the extracted DNA was checked by 
DeNovix Spectrophotometer (Resnova, Rome). 
The extracted DNA was sequenced using Ion S5™ System (Ion Torrent™) (ThermoFisher 
Scientific, Foster City, CA, USA) and Ion Customized Panel High Specificity designed by Ion 
Ampliseq Designer (ThermoFisher Scientific, Foster City, CA, USA). In this case study, the size of the 
panel was 16155 Kb and was expected to screen approximately 98.55% of the total panel with a 
minimum coverage of 20X. The panel included 24 genes, associated with RP and other retinal 
dystrophies. The selection of the genes was done on the basis of scientific literature, GeneReviews, 
and considering the frequency of pathogenic variants in the general population. A detailed 
description of the NGS panel has been summarized in Table 1.  
Table 1. Customized NGS panel utilized for molecular diagnosis of RP and other retinal dystrophies. 
Gene Locus OMIM 
Size of the 
target (bp) Exons Transcript ID 
Coverage 
(%) 
RHO 3q22.1 180380 1147 5 ENST00000296271.3 100 
PRPF31 19q13.42 606419 1760 14 ENST00000321030.8 100 
PRPH2 6p21.1 179605 1101 3 ENST00000230381.6 100 
RP1 8q11.2-
q12.1 
603937 6531 4 ENST00000220676.1 100 
IMPDH1 7q32.1 146690 2154 17 ENST00000338791.10 88.21 
Figure 1. Pedigree tree illustrating the possible autosomal-dominant transmission of disease within the
family of the proband. The red arrow indicates the proband.
To confir this hypothesis, the proband and the siblings were subjected to genetic testing to find
a olecular basis of their phenotypes. The genetic study was perfor ed according to the Declaration
of Helsinki, and all the participants provided signed infor ed consent. The study as approved by
the Ethics Co ittee of Santa Lucia Foundation (CE/PROG.650 approved on 01/03/2018).
Kit and MagPurix Automatic Extraction Sys em (Resnova) according to the ma ufacturer’s
instr ctions. The conce tration a d qu l ty of the ex racted DNA was checked by DeNovix
Spectrophotometer (Resnova, ome).
extracted DNAwas sequenc d using Ion S5™ System (Ion Torrent™) (ThermoFis Scientific,
Foster City, CA, USA) and Ion Customized Panel High Specificity designed by Ion Ampliseq Designer
(ThermoFisher Scientific, Foster City, CA, USA). In this case study, the size of the panel was 16155 Kb
and was expected to screen approximately 98.55% of the tot l panel with a minimum coverage of
20X. The panel included 24 genes, associated with RP and other ret nal dystrophies. The selection of
the genes was don on the basis of scientific literature, GeneReviews, and considering the frequ ncy
of pathogenic variants in th general opulation. A detailed description of the NGS panel has be n
summar zed in Table 1.
AmpliSeq libraries were generated using the Ion AmpliSeq™ Library Kit 2.0 (Thermofisher
Scientific, FosterCity, CA,USA) andprocessedwith IonChef™ Instrument (IonTorrent™, ThermoFisher
Scientific, Foster City, CA, USA) for template and enrichment procedures. Samples were subsequently
analyzed by Ion S5 System on Ion 520™ Chip (850 flows) (Thermo Fisher Scientific, Foster City,
CA, USA).
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Table 1. Customized NGS panel utilized for molecular diagnosis of RP and other retinal dystrophies.
Gene Locus OMIM Size of the Target (bp) Exons Transcript ID Coverage (%)
RHO 3q22.1 180380 1147 5 ENST00000296271.3 100
PRPF31 19q13.42 606419 1760 14 ENST00000321030.8 100
PRPH2 6p21.1 179605 1101 3 ENST00000230381.6 100
RP1 8q11.2-q12.1 603937 6531 4 ENST00000220676.1 100
IMPDH1 7q32.1 146690 2154 17 ENST00000338791.10 88.21
PRPF8 17p13.3 607300 7848 43 ENST00000304992.10 100
KLHL7 7p15.3 611119 2060 11 ENST00000339077.9 100
NR2E3 15q23 604485 1398 8 ENST00000617575.4 100
CRX 19q13.33 602225 960 4 ENST00000221996.11 91.77
PRPF3 1q21.2 607301 2352 16 ENST00000324862.6 100
TOPORS 9p21.1 609507 3198 3 ENST00000360538.6 100
USH2A 1q41 608400 17043 72 ENST00000307340.7 100
ABCA4 1p22.1 601691 7822 50 ENST00000370225.3 100
PDE6A 5q32 180071 3023 22 ENST00000255266.9 100
PDE6B 4p16.3 180072 3005 22 ENST00000496514.5 98.2
RPE65 1p31.3 180069 1882 14 ENST00000262340.5 100
CNGA1 4p12 123825 2460 10 ENST00000402813.7 100
BEST1 11q12.3 607854 2214 9 ENST00000449131.6 100
SEMA4A 1q22 607292 2566 15 ENST00000368285.7 99.96
EYS 6q12 612424 10368 43 ENST00000503581.5 100
CRB1 1q31.3 604210 4616 12 ENST00000367400.7 100
CERKL 2q31.3 608381 1957 13 ENST00000410087.7 90.5
RPGR Xp11.4 312610 4382 15 ENST00000378505.7 82.25
RP2 Xp11.3 300757 1153 5 ENST00000218340.3 100
Finally, the identified variant was confirmed by direct sequencing performed with BigDye
Terminator v3.1, BigDyeX Terminator and ABI3130xl (Applied Biosystem, Warrington, UK) according
to the manufacturer’s instructions.
2.3. Variant Interpretation
Data analysis and variant annotation were performed by the Ion Reporter Software 5.0 (Life
Technologies), Integrative Genomics Viewer (IGV) and TGex software. The interpretation of genetic
variants was conducted by Human GeneMutation Database (HGMD), Leiden Open Variation Database
(LOVD), Retinal International, ClinVar, GnomAD, 1000Genomes, and ExAC.
The functional e↵ect of the detected variants was evaluated by bioinformatic predictive tools such
as Mutation Taster, SIFT, PolyPhen 2, Human Splicing Finder (HSF), Varsome, Phyre2, VarSite, and
Missense3D. In particular, MutationTaster evaluates the potential pathogenic e↵ect of DNA sequence
alterations by predicting the functional consequences of amino acid substitutions, intronic and
synonymous alterations, short insertions and/or deletions (indels), and variants spanning intron-exon
borders a↵ecting splicing activity [10]. SIFT and PolyPhen2 provide a prediction of the functional e↵ect
of amino acid substitutions on proteins [11,12]. HSF predicts the e↵ects of variants on the splicing
mechanisms [13]. Varsome is a powerful annotation tool and search engine for human genomic
variants, allowing the classification of variants according to ACMG (American College of Medical
Genetics) criteria [14]. Phyre2, VarSite and Missense3D are able to analyze the e↵ect of amino acid
changes on protein structure, providing a 3D model of the predicted results [15–17]. Finally, variants
were classified according to the ACMG guidelines, which help provide clinical interpretation of
variants, by discriminating among benign, likely benign, uncertain significance, likely pathogenic and
pathogenic variants [18].
3. Results and Discussion
The proband (patient III: 4 in Figure 1) was analyzed by NGS panel, revealing a novel missense
variant (c.668T > A) in PRPH2 gene at the heterozygous state (Figure 2, left side). The variant was
confirmed by direct sequencing (Figure 2, right side).
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[21]. One of the most important domains of PRPH2 is the large D2 loop domain that extends for 142 
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report frequency data oncerning this variant, sugges ing that it has not been described in literature
or in any ther patient. Given these r sults, the presence of c.668T > A was tested among the family
m mbers of the p oband to investigate the familial segregation of the variant. The sequence analysis
revealed that the a↵ected sibling (patie t III: 2 in Figure 1) carries the same heterozygous variant in
PRPH2, whereas the healthy sibling (patient III: 3 in Figure 1) was wild-type. According t ACMG
guidelines, the c.668T > A can be cl ssified a a likely pathogenic variant, considering that:
• it is not described in the main databases (GnomAD, ExAc and 1000 Genomes) reporting variants
frequency in the general population;
• it is located in a gene with a low rate of benign missense variations;
• multiple bioinformatic tools reported c.668T > A as a disease-causing variant;
• it has not been found in more than 100 control tested subjects;
• patient’s phenotype or family history is highly specific for a disease with a single genetic etiology;
• it has been detected in a other a↵ected family me ber;
• PR H2 is a know causative gen accounting for ~5–10% of adRP cases [6,19]; and the resulting
amino acid change is located within a protein dom in harboring other misse se variants which
are known to be pathogenic for RP [20].
PRPH2 encodes a transmembrane glycoprotein called Peripherin-2/Retinal Degeneration Slow
(PRPH2/RDS, hereafter referred to as PRPH2), which is critical for the morphogenesis, maintenance
and stabilization of the disc rims of the outer segments in rod and cone photoreceptors. PRPH2 is able
to interact with itself and its homologue Rod Outer Segment Membrane protein 1 (ROM-1). PRPH2
and ROM-1 can interact together, forming homo- and hetero-tetramers which are further connected
by disulphide bounds to constitute high-order oligomers and allow disc rim formation [21]. One of
the most important domains of PRPH2 is the large D2 loop domain that extends for 142 amino acids
(from the 125th to the 163rd residue of protein) and is normally located within the intradiscal part of
the rim [20]. Considering the positioning of the I223N within PRPH2, the variant has been furtherly
investigated with Phyre2, Varsite and 3D missense bioinformatic tools that are able to analyze the
e↵ect of amino acid changes on protein structure, providing a 3D model of the predicted results.
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The prediction analysis showed that the amino acid substitution of an Asparagine residue (N, Asn)
with an Isoleucine (I; Ile) at the 223rd residue may be highly negative in terms of conserved amino
acid properties and, thus, modify the secondary and tertiary structures of PRPH2. Concerning this
hypothesis, it is important to remark that Ile is a non-polar hydrophobic amino acid whereas Asn is
a polar and hydrophilic residue, which may thereby alter the conformation and the localization of
the protein. The Phyre2 analysis predicted a disruption of the ↵-helical structures (in the residues
10–17, 86–95, 150–167, 239–250) within the variant protein (Figure 3), leading to a substantial di↵erent
conformation with respect to the wild-type (Figure 4).
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proband and the a↵ected sibling, although functional assays are necessary to confirm the real impact
of this variant on RP etiopathogenesis.
Supporting our results, di↵erent mutations have already been described within the D2 domain.
Similarly to our variant, most of them are missense, are localized within a specific D2 loop
region spanning from Lys193 to Glu226, and have been described as pathogenic for late-onset
adRP [20–22]. However, PRPH2 variants have also been involved in a wide range of autosomal
dominant retinal disorders, including RP, cone-rod dystrophy, adult vitelliform macular dystrophy,
cone dystrophy, and pattern dystrophy [20–22]. Such a high genetic heterogeneity further complicates
the genotype–phenotype correlations. In the present study, the genetic analysis was consistent with
the clinical diagnosis of RP, which has been probably transmitted by an autosomal-dominant pattern
within the family. This work described a novel variant in PRPH2 as a possible pathogenic mutation for
adRP, providing additional knowledge about the involvement of the D2 loop domain of PRPH2 in the
etiopathogenesis of retinal disorders. Moreover, the present study illustrates the clinical utility of NGS
panels to facilitate the genotype–phenotype correlations in retinopathies characterized by high genetic
heterogeneity and variable expressivity. The availability of analytical software for discriminating gene
variants on the basis of specific phenotype/disorders can improve the accuracy of the interpretation
and reduce the time required for providing the final response. From this perspective, individual
genetic profiles can be extremely helpful in combination with clinical and instrumental data to define a
comprehensive picture of the patient and calculate the recurrence risk of disease within the family and,
subsequently, in the o↵spring of a↵ected members [23,24].
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